Please use this identifier to cite or link to this item: 10.3892/mco.2017.1123
Title: Chromothripsis and progression-free survival in metastatic colorectal cancer
Authors: Skuja, Elina
Kalniete, Dagnija
Nakazawa-Miklaševiča, Miki
Daneberga, Zanda
Abolins, Arnis
Purkalne, Gunta
Miklasevics, Edvins
RSU Institute of Oncology
Keywords: metastatic colorectal cancer;chromothripsis;breakpoint instability index;progression-free survival;3.2 Clinical medicine;3.1 Basic medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;SDG 3 - Good Health and Well-being
Issue Date: Feb-2017
Citation: Skuja , E , Kalniete , D , Nakazawa-Miklaševiča , M , Daneberga , Z , Abolins , A , Purkalne , G & Miklasevics , E 2017 , ' Chromothripsis and progression-free survival in metastatic colorectal cancer ' , Molecular and Clinical Oncology , vol. 6 , no. 2 , pp. 182-186 . https://doi.org/10.3892/mco.2017.1123
Abstract: Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromothripsis and total breakpoint count (breakpoint instability index) on progression-free survival (PFS). A total of 19 patients with metastatic CRC (mCRC) receiving FOLFOX first‑line palliative chemotherapy between August, 2011 and October, 2012 were selected for this study. The results indicated that the highest breakpoint count was observed in chromosomes 1, 2 and 6. Chromothripsis was detected in 52.6% of the study patients. Furthermore, chromothripsis was associated with an increased median PFS (mPFS; 14 vs. 8 months, respectively; P=0.03), but an association with overall survival was not identified. The present study demonstrated that chromothripsis affected CRC patient survival, suggesting a role for this event as a prognostic and predictive marker in mCRC treatment.
DOI: 10.3892/mco.2017.1123
ISSN: 2049-9450
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:
File SizeFormat 
Chromothripsis_and_progression_free_survival.pdf906.36 kBAdobe PDFView/Openopen_acces_unlocked


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.